Q-omics provides the consensus-scored CYCSP32 profile across patient tissues and cancer cell-line models. CYCSP32 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, CYCSP32 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, CYCSP32 RNA expression shows 7,329 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, BRCA, and TGCT as cancer lineages where CYCSP32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP32 survival associations across molecular data types. CYCSP32 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP32 RNA expression–survival associations across cancer types. High CYCSP32 expression shows unfavorable associations in LUAD, COAD, UCS, MESO and READ, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify ESCA as the clearest survival context for CYCSP32 RNA expression.
This table summarizes CYCSP32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP32 shows higher tumor expression in BRCA, BLCA and KIRC. The BRCA box plot shows higher CYCSP32 RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p = .016).
This table shows molecular features associated with CYCSP32 in patient tissues and cancer cell lines. In patient samples, CYCSP32 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
